Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT01549951
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
50
Enrollment
INDUSTRY
Sponsor class
Conditions
Prostate Cancer
Interventions
DRUG:
Orteronel+Prednisone
Sponsor
Millennium Pharmaceuticals, Inc.